Existing dopaminergic therapies for Parkinson’s disease

Author： Dutta PhD Aloke K   Le MD   PhD Weidong  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.16, Iss.12, 2006-12, pp. : 1613-1625

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dopaminergic substitution in Parkinson’s disease

By Müller Thomas  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 10, 2002-10 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Non-dopaminergic drug treatment of Parkinson’s disease

By Müller T.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 557-572

Informa Healthcare

Access to resources Recommend Favorite

Rationale for current therapies in Parkinson’s disease

By Romrell Janet   Fernandez Hubert H   Okun Michael S  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1747-1761

Informa Healthcare

Access to resources Recommend Favorite

Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease

By Korczyn A.D.   Nussbaum M.  

Drugs, Vol. 62, Iss. 5, 2002-01 ,pp. : 775-786

Adis International

Access to resources Recommend Favorite

Protection of Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease by a Physically-Modified Saline Containing Charge-Stabilized Nanobubbles

By Khasnavis Saurabh   Roy Avik   Ghosh Supurna   Watson Richard   Pahan Kalipada  

Journal of Neuroimmune Pharmacology, Vol. 9, Iss. 2, 2014-03 ,pp. : 218-232

Springer Publishing Company

Access to resources Recommend Favorite